DiaMedica Therapeutics
DMAC
34 hedge funds and large institutions have $11.2M invested in DiaMedica Therapeutics in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 14 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
5.22% less ownership
Funds ownership: 20.14% → 14.93% (-5.2%)
21% less funds holding
Funds holding: 43 → 34 (-9)
33% less capital invested
Capital invested by funds: $16.9M → $11.2M (-$5.66M)
63% less call options, than puts
Call options by funds: $172K | Put options by funds: $465K
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLG
Cooperman Leon G
|
+$574K |
| 2 |
Two Sigma Investments
New York
|
+$284K |
| 3 |
Two Sigma Advisers
New York
|
+$259K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$131K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$78.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$1.14M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$973K |
| 3 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$906K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$694K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$557K |
DMAC Hedge Fund Activity: Q3 2021 in Review
34 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q3 2021, worth a combined $11.2M — down 33% from $16.9M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of DMAC and 5 opened new positions — a net loss of 9 holders — while 10 trimmed existing stakes and 13 added.
The largest buyer was Cooperman Leon G, adding an estimated $574K. The largest seller was Manatuck Hill Partners, cutting an estimated $1.14M.
- 34 institutional investors held DiaMedica Therapeutics (DMAC) as of Q3 2021, down from 43 in Q2 2021.
- Funds reported $11.2M of DiaMedica Therapeutics stock for Q3 2021, down 33% quarter-over-quarter.
- 5 funds opened new DiaMedica Therapeutics positions in Q3 2021 and 14 closed out, a net change of -9 holders.
- The largest DiaMedica Therapeutics buyer in Q3 2021 was Cooperman Leon G, an estimated $574K added.
- The largest DiaMedica Therapeutics seller in Q3 2021 was Manatuck Hill Partners, an estimated $1.14M sold.
Based on aggregated 13F filings for Q3 2021.